OBJECTIVE: The aim of this study was to verify the protective effect of hypertonic saline (HS) on brain endothelial cells under @entity519 conditions and the relevant underlying mechanism. METHODS: bEnd.3 cells were treated with @entity26 - @entity413 deprivation (OGD)-induced injury. To measure HS performance, cell viability was determined using the @entity15781 salt assay, and cell apoptosis was assessed by flow cytometry and @entity23929 UTP nick-end labeling staining. RNA-seq was performed to assess the expression profiles and screen the candidate genes that participated in OGD-induced @entity130 protective effect. Quantitative real-time polymerase chain reaction (qPCR) and western blot analysis were used to confirm the expression of candidate genes, and enzyme-linked immunosorbent assay was used to measure the level of @entity635 . Overexpression analyses were performed to confirm the functions of the differentially expressed genes. RESULTS: HS with a concentration of 40mmol/L @entity4202 had an obvious protective effect on bEnd.3 cells after OGD-induced injury, resulting in increased cell viability and a smaller percentage of apoptotic cells. According to the RNA-seq results, @entity12841 ( @entity12841 ) was chosen as the differentially expressed gene target in this study. The qPCR and western blot analyses further confirmed that the levels of @entity12841 /phosphorylated @entity12841 and @entity635 were enhanced after OGD-induced injury, but attenuated after treatment with 40mmol/L of @entity4202 HS. Overexpressed @entity12841 reversed the protective effect of HS that caused low viability and high rates of apoptosis in cells. CONCLUSION: HS can protect endothelial cells against OGD-induced injury, but is affected by the expression of @entity12841 /p- @entity12841 and @entity635 .

Hypertonic saline protects brain endothelial cells against XXXX correlated to the levels of estimated glomerular filtration rate and @entity635 .

@entity23929 :: ('21673(Tax:10090)', 'Gene') :: ['Terminal deoxynucleotidyl transferase'] @entity15781 :: ('MESH:C070380', 'Chemical') :: ['3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium'] @entity12841 :: ('13649(Tax:10090)', 'Gene') :: ['EGFR', 'epidermal growth factor receptor'] @entity635 :: ('16176(Tax:10090)', 'Gene') :: ['interleukin (IL)-1b', 'IL-1b'] @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen'] @entity4202 :: ('D012965', 'Chemical') :: ['NaCl'] @entity519 :: ('MESH:D000860', 'Disease') :: ['hypoxic'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity130 :: ('MESH:D014947', 'Disease') :: ['injury and the HS']
@entity519 :: (MESH:D000860,Disease) :: ['hypoxia']
